RESPIRATORY SYNCYTIAL VIRUS (RSV)
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV) explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS (RSV) trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New study tests RSV Vaccine's power to shield newborns
⭐️ VACCINE ⭐️ OngoingThis study looks at how well the RSV vaccine (ABRYSVO) given during pregnancy prevents serious RSV lung infections in babies. Researchers will review health records of infants hospitalized with breathing problems in Australia. No new treatments or visits are involved—just data an…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 05:25 UTC
-
Pregnancy vaccine shields infants from RSV in Real-World test
⭐️ VACCINE ⭐️ OngoingThis study checks how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV. Researchers will compare health outcomes of nearly 40,000 infants born to vaccinated versus unvaccinated mothers. The goal is to see if the vaccine reduces serious…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 05:23 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests a new mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy adults aged 18-45 and 60 or older will receive either the vaccine or a placebo. The main goals are to che…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:03 UTC
-
Scientists dive deep into RSV vaccine immune response
Knowledge-focused OngoingThis study looks at how the RSV vaccine affects the immune system in adults aged 60 and older. Researchers will measure antibodies and other immune markers in 14 volunteers over six months. The goal is to understand why the vaccine works and find early signs of a strong immune re…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE4 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 26, 2026 05:35 UTC